Using Apremilast to treat Erythema Multiforme

Apremilast for the Treatment of Refractory Erythema Multiforme

This study is testing if a medication called apremilast can help people with chronic erythema multiforme feel better and reduce their flare-ups.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 8 (estimated)
• Ages: 18 Years to 89 Years
• Sex: All
• Sponsor: University of Pennsylvania (other)
• Drugs / interventions: methotrexate
• Locations: 1 site (Philadelphia, Pennsylvania)
• Trial ID: NCT05875714 on ClinicalTrials.gov

What this trial studies

This clinical trial is focused on patients suffering from chronic, treatment-resistant erythema multiforme (EM), a condition that affects the skin and mucous membranes. Participants will receive apremilast, a medication currently approved for Behçet's Disease, for a duration of six months to assess its effectiveness in reducing pain and the frequency of EM flares. The study aims to determine if apremilast can provide a more consistent long-term management option for this challenging condition. Patients will be monitored for changes in their symptoms compared to their condition prior to treatment.

Who should consider this trial

Good fit: Ideal candidates are individuals with recurrent erythema multiforme who have not responded to standard therapies.

Not a fit: Patients with uncontrolled significant co-morbid conditions or those who have not experienced recurrent flares may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from chronic erythema multiforme.

How similar studies have performed: While apremilast has shown effectiveness in treating Behçet's Disease, its application for erythema multiforme is novel and has not been extensively tested.

Eligibility criteria

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study:

1. Presence of oral, genital, or cutaneous erythema multiforme (EM) diagnosed or confirmed by a dermatologist based on clinical and/or histopathologic data.
2. EM must be recurrent, defined as having =\>2 flares in the six months prior to enrollment (or =\>4 flares in the year prior to enrollment).
3. EM must be refractory to standard therapy defined as 3-month treatment course with valacyclovir and/or a systemic immunomodulatory therapy such as colchicine, dapsone, azathioprine, mycophenolate mofetil, or methotrexate.
4. Must be in general good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).
5. Willing and able to provide personally signed and dated informed consent form.
6. Stated willingness and ability to comply with all study procedures including adhering to oral apremilast regimen and availability for the duration of the study.
7. Adults aged 18-89 years old.
8. People of childbearing potential (PCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, PCBP who engage in activity by which conception is possible must use one of the approved contraceptive options described below:

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: External or internal condom (latex condom or nonlatex condom NOT made out of natural \[animal\] membrane \[for example, polyurethane\]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

NOTE: This criterion is satisfied as "not applicable" (N/A) for those who practice abstinence as part of their usual and customary way of life, so long as this is maintained throughout study period plus 28 days post-treatment; are postmenopausal; or are of male sex/assigned male at birth (AMAB).

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment:

1. Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinological, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
2. Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if they were to participate in the study.
3. Prior history of unmanaged depressive symptoms, suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
4. A score of 4 or higher on Patient Health Questionnaire at screening.
5. Pregnant or breast feeding.
6. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
7. Malignancy or history of malignancy, except for:

   1. treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas;
   2. treated \[ie, cured\] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix with no evidence of recurrence within the previous 5 years.
8. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
9. Prior treatment with apremilast.
10. Patient unable to comply with study or conform to treatment diary or regular follow up visits.
11. Patients with ocular EM.
12. Concomitant use of immunosuppressive medications for treatment of other diseases.
13. Patients with contraindications to Apremilast according to package insert.

Where this trial is running

Philadelphia, Pennsylvania

• Perelman Center For Advanced Medicine — Philadelphia, Pennsylvania, United States (RECRUITING)

Study contacts

• Principal investigator: Robert G Micheletti, MD — University of Pennsylvania
• Study coordinator: Joshua S Bryer, BA

Conditions: Erythema Multiforme